Kötü Prognostik Özelliklere Sahip Mide Kanserinde D2 Diseksiyon ve Karaciğer Metastazektomi Sonrası Gözlenen Üç Yıllık Hastalıksız Sağkalım: Olgu Sunumu

Yıl 2017, Cilt: 3 Sayı: 1, 49 - 52, 01.01.2017

Aydın Aytekin Süleyman Şahin Muhammet Bekir Hacıoğlu Fatih Karataş Mustafa Altınbaş

Öz

Karaciğer metastazı olan mide kanserlerinin optimal tedavisi kemoterapi olsa da hepatektomi sonrası daha iyi sağkalım gösteren bazı yayınlar vardır. Metastatik mide kanserinde hepatektomi sonrası sağkalımı etkileyen farklı faktörler olabilir, örneğin invazyon derinliği, lenfatik invazyon, histoloji, metastaz sayısı, metastazektomi zamanı ve metastazın cerrahi sınırı gibi. Bu olguda tanı anında D2 diseksiyon ve karaciğer metastazektomi uygulanan mide kanseri olgusunda cerrahinin önemini vurgulamayı amaçladık. Literatürle karşılaştırdığımızda bizim olgumuzda nöral/lenfovasküler invazyon, periferik doku invazyonu, lenf nodu invazyonu ve tümör genişliğinin fazla olması gibi birçok olumsuz faktör mevcuttu. Bunlara karşın bizim hastamızda literatürdeki olgulara göre daha uzun bir hastalıksız sağkalım saptandı

Anahtar Kelimeler

Mide kanseri, Hepatik metastazektomi, D2 diseksiyon, Hastalıksız sağkalım

Three-Year Disease-Free Survival After D2 Dissection and Liver Metastasectomy in a Gastric Cancer Case with Poor Prognostic Factors: A Case Report

Öz

Although the optimal treatment for hepatic metastasis from gastric cancer is chemotherapy, there are a few reports showing better survival after hepatectomy. Various factors such as depth of invasion, lymphatic invasion, histology, number of metastases, time of metastasectomy and surgical margins for hepatic tumors may be associated with the outcome after hepatic metastasectomy in patients with gastric cancer metastasis. Herein we aimed to emphasize the importance of surgical excision in a patient with gastric cancer who underwent surgery of D2 dissection and liver metastasectomy at the time of diagnosis. Compared to the literature cases, our case had many different poor prognostic factors such as neural/lymphovascular invasion, peripheral tissue invasion, lymph node invasion and the size of the tumor. However, our patient had longer disease-free survival compared to the literature cases

Anahtar Kelimeler

Gastric cancer, Hepatic metastasectomy, D2 dissection, Disease-free survival

Kaynakça

• 1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
• 2. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK Jr, Warren G, Washington MK, Willett C, Wright CD, McMillian NR, Sundar H. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2013; 11(5): 531-46.
• 3. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24(18): 2903-9.
• 4. Choi IS, Oh DY, Kim BS, Lee KW, Kim JH, Lee JS. Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer. Cancer Res Treat 2007; 39(3): 99-103.
• 5. Kodera Y, Fujitani K, Fukushima N, Ito S, Muro K, Ohashi N, Yoshikawa T, Kobayashi D, Tanaka C, Fujiwara M. Surgical resection of hepatic metastasis from gastric cancer: A review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer 2014;17(2): 206-12.
• 6. Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Yoshidome H, Shimizu Y, Nakajima N. Benefits and limits of hepatic resection for gastric metastases. Am J Surg 2001; 181(3): 279-83.
• 7. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Naka T, Ishida K, Ojima T, Yamaue H. Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg 2009; 394(4): 647-53.
• 8. Garancini M, Uggeri F, Degrate L, Nespoli L, Gianotti L, Nespoli A, Uggeri F, Romano F. Surgical treatment of liver metastases of gastric cancer: Is local treatment in a systemic disease worthwhile? HPB (Oxford) 2012; 14(3): 209-15.
• 9. Tsujimoto H, Ichikura T, Ono S, Sugasawa H, Hiraki S, Sakamoto N, Yaguchi Y, Hatsuse K, Yamamoto J, Hase K. Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int 2010; 4(1): 406-13.
• 10. Maehara Y, Moriguchi S, Kakeji Y, Kohnoe S, Korenaga D, Haraguchi M, Sugimachi K. Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery 1991; 110(5): 820-3.
• 11. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002; 5(1): 1-5